SB-215505

SB-215505 is a compound that is used in scientific research. It acts as a potent and selective antagonist for the 5-HT2B receptor, with around 100x selectivity over other related targets.<ref>,

 SB-215505, a selective 5-HT2B receptor antagonist, potentiates haloperidol-induced dopamine release in rat striatum and nucleus accumbens, 
 Neuropharmacology, 
 2000,
 Vol. 39(Issue: 5),
 pp. 793–802,
 DOI: 10.1016/S0028-3908(99)00168-6,
 PMID: 10728886,</ref>

Pharmacology

SB-215505 has been used in the study of various diseases and conditions, including schizophrenia, depression, and anxiety disorders. It has been shown to potentiate the effects of other drugs, such as haloperidol, in the brain.<ref>,

 SB-215505, a selective 5-HT2B receptor antagonist, potentiates haloperidol-induced dopamine release in rat striatum and nucleus accumbens, 
 Neuropharmacology, 
 2000,
 Vol. 39(Issue: 5),
 pp. 793–802,
 DOI: 10.1016/S0028-3908(99)00168-6,
 PMID: 10728886,</ref>

Research

Research on SB-215505 has focused on its potential therapeutic applications. Studies have suggested that it may have potential in the treatment of conditions such as Parkinson's disease, obsessive-compulsive disorder, and eating disorders.<ref>,

 SB-215505, a selective 5-HT2B receptor antagonist, potentiates haloperidol-induced dopamine release in rat striatum and nucleus accumbens, 
 Neuropharmacology, 
 2000,
 Vol. 39(Issue: 5),
 pp. 793–802,
 DOI: 10.1016/S0028-3908(99)00168-6,
 PMID: 10728886,</ref>

See also

• 5-HT2B receptor
• Haloperidol
• Neuropharmacology

References

<references />

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia

SB-215505

• 
  SB-215505